View Cancer Clinical Trials
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
|North Coast Cancer
- To determine the effect of chemotherapy in patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®. In patients with 1-3 positive nodes, and hormone receptor (HR)-positive, HER2-negative breast cancer with RS ≤ 25 treated with endocrine therapy we will test whether the difference in disease-free survival for patients treated with chemotherapy compared to no chemotherapy depends directly on the magnitude of RS. If benefit depends on the RS score, the trial will determine the optimal cutpoint for recommending chemotherapy or not.
- To compare overall survival (OS), distant disease-free survival (DDFS) and local disease free interval (LDFI) by receipt of chemotherapy or not and its interaction with RS.
- To compare the toxicity across the treatment arms.
- To perform other assays or tests (in particular the PAM50 risk of relapse score), as they are developed and validated, that measure potential benefit of chemotherapy and compare them to Oncotype DX®.
- To determine the impact of management with Oncotype DX® on patient-reported anxiety (co-primary Health-Related Quality of Life [HRQL] outcome) prior to screening, after disclosure of test results, and during the randomized trial.
- To determine the impact of Oncotype DX® on the initial management cost of node-positive, HR-positive, HER2-negative breast cancer.
- To compare patient-reported utilities (e.g. QOL) for those randomized to chemotherapy versus no chemotherapy.
- Using modeling and DFS information from the trial, to estimate the cost-effectiveness of management with Oncotype DX® vs. usual care.
- To determine the role of other assays (e.g. PAM50) as predictors of DFS, DDFS and LDFI for patients randomized to chemotherapy versus no chemotherapy.
- To determine the impact of treatment with chemotherapy versus no chemotherapy on patient-reported fatigue and cognitive concerns (secondary HRQL outcomes).
- To determine the impact of management with Oncotype DX® on patient-reported decision conflict, perceptions regarding Oncotype DX® testing, and survivor concerns prior to screening, after disclosure of test results, and during the randomized trial (secondary HRQL outcomes).
Step 1 Registration (Oncotype DX® Screening)
- Patients must have a histologically confirmed diagnosis of node positive (1-3 nodes) invasive breast carcinoma with positive estrogen and/or progesterone receptor status, and negative HER-2. Estrogen and progesterone receptor positivity must be assessed according to ASCO/CAP guidelines as either ER or PR ≥ 1% positive nuclear staining. HER-2 test result negativity must be assessed as per ASCO/CAP 2013 guidelines using IHC, ISH or both. HER-2 is negative if a single test (or all tests) performed in a tumor specimen show: a) IHC negative (0 or 1+) or b) ISH negative using single probe or dual probe (average HER-2 copy number < 4.0 signals per cell by single probe or HER-2/CEP ration < 2.0 with an average copy number < 4.0 signals per cell by dual probe). If HER-2 IHC is 2+, evaluation for gene amplification (ISH) must be performed and the ISH must be negative; ISH is not required if IHC is 0 or 1+. HER-2 equivocal is not eligible.
- Patients with multifocal, multicentric and synchronous bilateral breast cancers are allowed.
- Multifocal disease is defined as more than one invasive cancer < 2 cm from the largest lesion within the same breast quadrant. (NOTE: The Oncotype DX® testing must be completed on the largest lesion.)
- Multicentric disease is defined as more than one invasive cancer ≥ 2 cm from the largest lesion within the same breast quadrant or more than one lesion in different quadrants. (NOTE: Oncotype DX® testing should be completed on all tumors and the determination for eligibility should be made on the highest recurrence score.)
- Synchronous bilateral disease is defined as invasive breast cancer with positive lymph nodes (axillary or intramammary) in at least one breast, diagnosed within 30 days of each other. (NOTE: The Oncotype DX® testing should be completed on both tumors and the tumor with the highest recurrence score should be used.)
- Patients will have undergone axillary staging by sentinel node biopsy or axillary lymph nodes dissection (ALND). Patients must have at least one, but no more than three known positive lymph nodes (pN1a, pN1b or pN1c), see Section 4.0 for definitions. Patients with positive sentinel node are not required to undergo full axillary lymph node dissection. This is at the discretion of the treating physician. Axillary node evaluation is to be performed per the standard of care at each institution. Patients with micrometastases as the only nodal involvement (pN1mi) are not eligible.
- Patients must not have inflammatory breast cancer and must not have metastatic disease. Patients with a prior diagnosis of DCIS are eligible if they received mastectomy alone (no therapeutic radiation, intraoperative radiation, or endocrine therapy). Radiation in the opposite breast is acceptable. Partial breast irradiation (including brachytherapy) is not allowed.
- Patients must have had either breast-conserving surgery with planned radiation therapy or total mastectomy (with or without planned postmastectomy radiation). Patients must have clear margins (as per local institutional guidelines).
- Registration of patients who have not yet undergone Oncotype DX® screening must occur no later than 56 days after definitive surgery. (For all patients, Step 2 Registration must occur within 84 days after definitive surgery.) If the Oncotype DX® Breast Cancer Assay has not been performed, patients must be willing to submit tissue samples for testing to determine the Recurrence Score value. A representative block or unstained sections from the representative block are sent directly to Genomic Health for Oncotype DX® Breast Cancer Assay which will be performed according to the standard commercial process (see Section 15.1).
- Patients must be females ≥ 18 years of age. As the Oncotype DX Recurrence Score has not been validated in men with breast cancer, men are not eligible for this study.
- Patients must have a complete history and physical examination within 28 days prior to registration
- Patients must have a performance status of 0-2 by Zubrod criteria (see Section 10.7).
- Patients must be able to receive taxane and/or anthracycline based chemotherapy.
- Patients must not have begun chemotherapy or endocrine therapy for their breast cancer prior to registration.
- Patients must not require chronic treatment with systemic steroids or other immunosuppressive agents (inhaled steroids are allowed).
- Patients must not have received an aromatase inhibitor (AI) or a selective estrogen receptor modulator (SERM) such as tamoxifen or raloxifene within 5 years prior to registration
- Patients must not be pregnant or nursing due to the possibility of harm to a fetus or nursing infant from this treatment regimen. Women of reproductive potential must have agreed to use an effective contraceptive method. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures.
- No other prior malignancy is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years.�
- The Quality of Life and Economic Substudy is permanently closed to accrual effective 12/1/12. Patients who consented to QOL prior to 12/1/12 should continue to complete QOL forms per their expectation report. Patients who are able to complete a questionnaire in English must be offered the opportunity to participate in the Quality of Life and Economic Substudy. (The Quality of Life and Economic Substudy is available to U.S. INSTITUTIONS ONLY.) Patients who are not able to complete a questionnaire in English are registered to S1007 without participating in the Quality of Life and Economic Substudy.
- Patients who consent to participate in the Quality of Life and Economic Substudy and who do not yet know the results of their Oncotype DX® screening must have completed the S1007 Health-Related Quality of Life Questionnaire: Enrollment form within 14 days prior to Step 1 Registration.
- Patients who consent to participate in the Quality of Life and Economic Substudy and who do already know their Oncotype DX® Recurrence Score (and it is 25 or less) will proceed to Step 2 Registration without completing the S1007 Health-Related Quality of Life Questionnaire Enrollment form (but will complete the S1007 Health-Related Quality of Life Questionnaire: Randomized Study form as outlined in Section 5.19).
- Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines. For Step 1 registration of patients who have not yet submitted specimens for the Oncotype DX® Breast Cancer Assay, the appropriate consent form is the Step 1 Consent Form. For both Step 1 and Step 2 registration of patients whose Recurrence Score is already known and is 25 or less, the appropriate consent form is the Step 2 Consent Form.
- As a part of the OPEN registration process (see Section 13.4 for OPEN access instructions) the treating institution’s identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
Step 2 Registration (Randomization)
- Recurrence score (RS) by Oncotype DX® must be ≤ 25.
- Step 2 Registration must take place within 84 days after definitive surgery. Patients must not have begun chemotherapy or endocrine therapy for their breast cancer prior to randomization.
- Patients randomized to either arm may also co-enroll in Phase III trials that compare local therapies, or compare systemic therapies (not including chemotherapy). Patients randomized to chemotherapy may also co-enroll in Phase III trials that compare chemotherapies.
- The Quality of Life and Economic Substudy is permanently closed to accrual effective 12/1/12. Patients at U.S. INSTITUTIONS who consent to participate in the Quality of Life and Economic Substudy must agree to complete the S1007 Health-Related Quality of Life Questionnaire: Randomized Study Form after Recurrence Score results and randomized treatment status are known but before treatment has been initiated.
- Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines. For all patients the appropriate consent form for this registration is the Step 2 Consent Form.
Exclusion Criteria Not Available
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2014 Cleveland Clinic. All rights reserved.